Evidence map›Paper›PMID 36985644›Full record

ArticleMolecules (Basel, Switzerland)2023

Design of the New

Valeria I Raskolupova, Meiling Wang, Maya A Dymova, Gleb O Petrov, Ivan M Shchudlo, Sergey Yu Taskaev, Tatyana V Abramova, Tatyana S Godovikova, Vladimir N Silnikov, Tatyana V Popova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Valeria I RaskolupovaInstitute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.
Meiling WangFaculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.
Maya A DymovaInstitute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.ORCID 0000-0002-7281-9096
Gleb O PetrovInstitute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.ORCID 0000-0002-2924-5920
Ivan M ShchudloBudker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia.
Sergey Yu TaskaevFaculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.ORCID 0000-0002-5313-2563
Tatyana V AbramovaInstitute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.ORCID 0000-0003-1187-5542
Tatyana S GodovikovaInstitute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.
Vladimir N SilnikovInstitute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.
Tatyana V PopovaInstitute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.ORCID 0000-0002-1098-8628
Institute of Chemical Biology and Fundamental Medicine · RUNovosibirsk State University · RUSiberian Branch of the Russian Academy of Sciences · RU

Funding

Russian Science Foundation 19-74-20123
6 · The paper itself

Abstract

Combination therapy is becoming an increasingly important treatment strategy because multi-drugs can maximize therapeutic effect and overcome potential mechanisms of drug resistance. A new albumin-based theranostic containing gemcitabine

Indexed as

GemcitabinePrecision MedicineAlbuminsBoron CompoundsHumansAlbuminsBoron CompoundsdodecaborateGemcitabineboronated albumin theranostic conjugateboron delivery agentsboron neutron capture therapycell viability and proliferationclonogenic assaygemcitabine analogue

Identifiers

PMID36985644
PMCPMC10056911
OpenAlexW4327617263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.